Theraclion Sucessfully Representated at the 8th International Symposium on Focused Ultrasound
14 Novembre 2022 - 6:15PM
Business Wire
Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE)
(Paris:ALTHE), an innovative company developing a robotic
platform for non-invasive echotherapy, shared its clinical
advances at the International Symposium of Focused Ultrasound
Bethesda (USA) which ended on October 27th: the opportunity for
Theraclion’s key opinion leaders to present to the scientific
community their ongoing work in the management of varicose veins,
thyroid nodules and breast cancer.
SONOVEIN®: similar success rates to "invasive"
techniques
The latest advances of SONOVEIN® in addition to studies already
carried out or in progress validate the effectiveness of this
non-invasive solution at a level like that of thermal endovascular
techniques. Unlike with other techniques, patients can be treated
and resume normal activity immediately. Dr. Steve Elias, Director
of the Center for Venous Diseases at Englewood Hospital (New
Jersey) presented top-line results from 20 patients treated with
SONOVEIN® HD, all enrolled in an FDA-approved clinical trial. 95%
of cases had no reflux after one week – this percentage grew to
100% for the patients seen at the end of the 3-month observation
period. Dr. Ruben Rodriguez Carvajal, Director of the International
Vascular and Endovascular Institute of Marbella (Spain) presented
preliminary results on 47 patients treated with SONOVEIN®S. These
data show an overall average occlusion rate of 90% of veins treated
after 3 months. According to him, "echotherapy is the treatment of
the future".
Echopulse®, excellent results for the treatment of
thyroid nodules without surgery
Numerous clinical studies have shown that HIFU (High-Intensity
Focused Ultrasound) treatment is effective in reducing the volume
of symptomatic thyroid nodules, but also in relieving symptoms.
This is what was highlighted by Pr. Brian Lang, Chief of Division
of Endocrine Surgery at Queen Mary Hospital, Hong Kong (China): His
study with a 2-year follow-up (108 patients) consisted of
performing a single session HIFU ablation of benign thyroid nodules
and showed a reduction in volume of 70%.
According to him, Echopulse® technology is an effective and safe
treatment for benign thyroid nodules, with similar efficacy to
so-called "minimally invasive" techniques. A single ablation
session can significantly reduce the nodule size and improve
symptoms, unlike laser and radiofrequency techniques which often
require more than one session in his experience.
Theraclion's technology in the treatment of breast
cancer
After a successful first collaboration with patients with
advanced breast cancer, the University of Virginia Cancer Center
(UVA) has expanded the use of Theraclion's technology to a Phase 2
for early-stage breast cancer.
Prof. David Brenin, Head of Breast and Melanoma Surgical
Services at UVA, presented this ongoing study evaluating the
combined effect of Theraclion's focused ultrasound and low-dose
chemotherapy in patients with early-stage breast cancer. Started
only a few months ago, this first study evaluates whether this
combination decreases myeloid-derived suppressor cells and thus
increases the immune response of patients. If proven effective,
this combination treatment could offer patients with early-stage
breast cancer a better chance of survival. 3 patients are currently
being treated.
About Theraclion At Theraclion we believe that surgery,
as we know it, is outdated. It converts optimistic patients into
anxious individuals, brilliant doctors into exhausted system
executors and stretches healthcare systems to the limit. We have
disrupted this convention by creating extracorporeal treatment
platforms. We replace surgery with a robotic treatment from outside
the body using High Intensity Focused Ultrasound (HIFU). Our
leading edge echotherapy platforms are currently CE marked in
non-invasive treatment of varicose veins with SONOVEIN® and of
breast fibroadenomas and thyroid nodules with Echopulse®. Located
in Malakoff, near Paris, our employees live and breathe innovation
by extensive clinical research and harness artificial intelligence.
The market of varicose veins treatment alone requires around 5
million procedures annually. It is a dynamic market in which we
change paradigms by making non-invasive echotherapy the new
standard. For more information, please visit www.theraclion.com
and our patient website www.echotherapy.com.
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221114005814/en/
Theraclion David AUREGAN CEO
david.auregan@theraclion.com
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024